The latest announcement is out from GlucoTrack ( (GCTK) ).
Glucotrack, Inc. has begun enrolling patients for its short-term clinical study of a novel continuous blood glucose monitor designed for real-time, accurate blood readings without external components. This implantable device promises a less intrusive solution for diabetes management, with study results anticipated within 6-8 weeks. The study is led by renowned cardiologist Dr. Alexandre Abizaid and conducted at Brazil’s top cardiology hospital.
Find detailed analytics on GCTK stock on TipRanks’ Stock Analysis page.